An Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BTCT4465A in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Conditions

Lymphoid Leukemia | Non-Hodgkin's Lymphoma | Phase I

Phase I

Volunteers
Health Professionals

What is the purpose of this trial?

This study is designed to evaluate the safety and pharmacokinetics of BTCT4465A when administered as a single agent by intravenous (IV) infusion to participants with relapsed or refractory B-cell NHL and CLL. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.

Find out more about who can participate in this trial

Trial with
Genentech, Inc.
Start Date
04/26/2022
End Date
10/31/2020

For more information about this study, contact:

Kylie Boyhen

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Volunteer Now

Principal Investigator

Iris Isufi, MD
Associate Professor of Medicine (Hematology); Co-Director Adult CAR T-Cell Therapy Program, Hematology; Co-Leader, Cellular Therapy Disease Aligned Research Team (DART), Yale Cancer Center; Co-Chair, Cellular Therapy (CT)-SAFE Committee, Yale Cancer Center

Sub-Investigators

Last Updated
04/28/2022
Study HIC
#1509016491

An Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BTCT4465A in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Conditions

Volunteers

Health Professionals

What is the purpose of this trial?

I'm interested in volunteering

Principal Investigator

Sub-Investigators

Contact Information